Dyspepsia and disease burden among patients with atrial fibrillation

Critical Pathways in Cardiology

Volumn 11, Issue 1, 2012, Pages 14-19

  Lamori, Joyce C ^a   Mody, Samir H ^a   Gross, Hillary J ^b   Dibonaventura, Marco Dacosta ^b   Patel, Aarti ^a   Schein, Jeffrey ^a   Nelson, Winnie W ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^b KANTAR HEALTH   (United States)

Author keywords

atrial fibrillation; dyspepsia; economic impact; health related quality of life

Indexed keywords

ANTICOAGULANT AGENT;

ADULT; AGED; ARTICLE; CARDIAC PATIENT; CARDIOVASCULAR RISK; COMORBIDITY; CONTROLLED STUDY; DEMOGRAPHY; DYSPEPSIA; FEMALE; HEALTH CARE; HEALTH CARE UTILIZATION; HEART ATRIUM FIBRILLATION; HUMAN; INTERNET; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; MULTIPLE REGRESSION; OBSERVATIONAL STUDY; PREVALENCE; PRIORITY JOURNAL; PRODUCTIVITY; QUALITY OF LIFE; QUESTIONNAIRE; RETROSPECTIVE STUDY; STROKE; UNITED STATES;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; COMORBIDITY; COST OF ILLNESS; DYSPEPSIA; FEMALE; HUMANS; MALE; MEDICATION ADHERENCE; MEDICATION THERAPY MANAGEMENT; MULTIVARIATE ANALYSIS; PREVALENCE; QUALITY OF LIFE; RETROSPECTIVE STUDIES; RISK ADJUSTMENT; RISK FACTORS; STROKE; UNITED STATES;

EID: 84857816634     PISSN: 1535282X     EISSN: 15352811     Source Type: Journal    
DOI: 10.1097/HPC.0b013e318246fae8     Document Type: Article

References (22)

1. Naccarelli GV, Varker H, Lin J, et al. Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol. 2009;104:1534-1539.
2. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. JAMA. 2001;285:2370-2375.
3. Ford AC, Forman D, Bailey AG, et al. Initial poor quality of life and new onset of dyspepsia: Results from a longitudinal 10-year follow-up study. Gut. 2007;56:321-327.
4. Sobieraj DM, Coleman SM, Coleman CI. US prevalence of upper gastrointestinal symptoms: A systematic literature review. Am J Manag Care. 2011; 17:e449-e458.
5. Crane SJ, Talley NJ. Chronic gastrointestinal symptoms in the elderly. Clin Geriatr Med. 2007;23:721-734.
6. Welén K, Faresjö A, Faresjö T. Functional dyspepsia affects women more than men in daily life: A case-control study in primary care. Gend Med. 2008;5:62-73.
7. Talley NJ, Locke GR III, Lahr BD, et al. Functional dyspepsia, delayed gastric emptying, and impaired quality of life. Gut. 2006;55:933-939.
8. Aro P, Talley NJ, Agréus L, et al. Functional dyspepsia impairs quality of life in the adult population. Aliment Pharmacol Ther. 2011;33:1215-1224.
9. Bunch TJ, Packer DL, Jahangir A, et al. Long-term risk of atrial fibrillation with symptomatic gastroesophageal reflux disease and esophagitis. Am J Cardiol. 2008;102:1207-1211.
10. Kunz JS, Hemann B, Edwin Atwood J, et al. Is there a link between gastroesophageal reflux disease and atrial fibrillation? Clin Cardiol. 2009;32: 584-587.
11. Weigl M, Gschwantler M, Gatterer E, et al. Reflux esophagitis in the pathogenesis of paroxysmal atrial fibrillation: Results of a pilot study. South Med J. 2003;96:1128-1132.
12. Gerson LB, Friday K, Triadafilopoulos G. Potential relationship between gastroesophageal reflux disease and atrial arrhythmias. J Clin Gastroenterol. 2006;40:828-832.
13. Adachi JD, Faraawi RY, O'Mahony MF, et al. Upper gastrointestinal tolerability of alendronate sodium monohydrate 10 mg once daily in postmenopausal women: A 12-week, randomized, double-blind, placebo-controlled, exploratory study. Clin Ther. 2009;31:1747-1753.
14. Niculescu L, Li C, Huang J, et al. Pooled analysis of GI tolerability of 21 randomized controlled trials of celecoxib and nonselective NSAIDs. Curr Med Res Opin. 2009;25:729-740.
15. Mallen SR, Essex MN, Zhang R. Gastrointestinal tolerability of NSAIDs in elderly patients: A pooled analysis of 21 randomized clinical trials with celecoxib and nonselective NSAIDs. Curr Med Res Opin. 2011;27:1359-1366.
16. Watson DJ, Bolognese JA, Yu C, et al. Use of gastroprotective agents and discontinuations due to dyspepsia with the selective cyclooxygenase-2 inhibitor etoricoxib compared with non-selective NSAIDs. Curr Med Res Opin. 2004;20:1899-1908.
17. Connolly SJ, Ezekowitz MD, Yusuf S, et al. RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-1151.
18. Bhatt DL, Cryer BL, Contant CF, et al; COGENT Investigators. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med. 2010;363:1909-1917.
19. Hungin AP, Rubin GP, O'Flanagan H. Co-prescription of H2 receptor blockers and proton pump inhibitors with warfarin in general practice. Postgrad Med J. 1999;75:721-722.
20. Ware JE, Kosinski M, Turner-Bowker DM, et al. How to Score Version 2 of the SF-12 Health Survey. Lincoln, RI: QualityMetric Incorporated; 2005.
21. Brook RA, Kleinman NL, Choung RS, et al. Functional dyspepsia impacts absenteeism and direct and indirect costs. Clin Gastroenterol Hepatol. 2010; 8:498-503.
22. Brook RA, Kleinman NL, Choung RS, et al. Excess comorbidity prevalence and cost associated with functional dyspepsia in an employed population. Dig Dis Sci. 2011 Jul 13. [Epub ahead of print].